Depth of Response to Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone Improves over Time in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma: Griffin Study Update

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Introduction: DARA, a human IgGκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care (SoC) regimens for multiple myeloma (MM). In randomized studies, DARA-based regimens significantly improved response rates, depth of response including minimal residual disease (MRD) negativity, and progression-free survival (PFS) in NDMM and relapsed/refractory MM pts. RVd followed by high-dose therapy (HDT), autologous stem cell transplant (ASCT), and consolidation is a SoC regimen for US pts with NDMM. This phase 2, randomized study (GRIFFIN; NCT02874742) evaluated DARA plus RVd (D-RVd) in ASCT-eligible NDMM pts. A 16-pt safety run-in showed no safety concerns. Here, we present results that adding DARA to RVd improves responses rapidly, including depth of response, which increases with longer duration of therapy.

Conclusions: These data demonstrate that adding DARA to RVd significantly improves response rates and depth of response, including sCR and MRD negativity. As seen in other randomized studies, continued use of daratumumab improved depth of response. The overall safety profile of D-RVd is consistent with previous reports with DARA plus SoC. Likewise, similar to what was reported from CASSIOPEIA, stem cell mobilization and ASCT are feasible with D-RVd, without a significant effect on hematopoietic reconstitution. The study is ongoing, with pts continuing maintenance therapy.


ABOUT PETER M. VOORHEES, MD

PETER M. VOORHEES, MD Dr. Peter Voorhees is a board certified Hematologist and the Director of Outreach for Hematologic Malignancies, Plasma Cells Disorder Program in the Department of Hematologic Oncology and Blood Disorders at Levine Cancer Institute, Charlotte, North Carolina. His research focuses on the development of novel therapeutic strategies for the treatment of multiple myeloma. Visit Dr. Peter Voorhees’ full biography.p>

Subheader
ASH 2019
Video
IMF TV Blog Category
Old Id
2486

Source URL: https://www.myeloma.org/videos/depth-response-daratumumab-lenalidomide-bortezomib-dexamethasone-improves-over-time-patients